Lyonbiopole and 20 Members of Their Group Took Part in This Strategic Event to Internationally Promote and Endorse the Rhone-Alpes' Rich and Varied Biotech Ecosystem
LYON, FRANCE--(Marketwired - Jul 28, 2015) - Lyonbiopole, leader in the life science industry, showcased at the BIO International Convention for the ninth consecutive year, celebrating an impressive delegation, influential awards and announcements, and renewed ties with partners on the American East Coast. Participants of the Lyonbiopole mission included Adocia, Alaxia, Alizé Pharma, BIOASTER, CapEval Pharma, CEA Leti, Cytoo, ElsaLys Biotech, ERYtech Pharma, Eveon, Flamel Technologies, Genoway, ImmunID, Kallistem, Maat Pharma, Newtone Technologies, Orega Biotech, PDC*line Pharma, TransCure bioServices and Transgene.
"BIO 2015 was once again very successful for our members, and especially for the SMEs that benefit from the unmatched opportunity to exchange with peers, enrich innovation roadmaps and to create new contacts that could potentially lead to investment, partnership and research collaboration," shared Florence Agostino-Etchetto, Director General of Lyonbiopole.
The delegation coordinated and accompanied by Lyonbiopole was the largest French group to attend the event. Funded by Rhône-Alpes Regional Council, Lyon Metropole and Grenoble Metropole, Lyonbiopole marked their tenth anniversary by showcasing the wealth, dynamism and maturity of the Rhône-Alpes life sciences cluster.
Illustrating this exuberant ecosystem, PDC*line Pharma announced at BIO 2015 that PDC*vac, its new line of anti-cancer vaccines based on a line of plasmacytoid dendritic cells (PDC*line), has been awarded the MTI (medicine of innovative therapy) classification by the Committee of Innovative Therapies and the EMA (European Medicines Agency), with support from the European Commission. The EMA/CAT considers that PDC*vac corresponds to the definition of an MTI in the category of somatic cell therapy medicine.
Three event highlights:
In addition, this exhibition gave Lyonbiopole the opportunity to reinforce relations with several international partners, including the city of Boston where Lyon launched the Big Booster program, the Massachusetts Life Sciences Center, and the Research Triangle of North Carolina.
Lyonbiopole's members are already looking forward to BIO 2016 when the international convention will take place in San Francisco.
About Lyonbiopole
As a biocluster, Lyonbiopole is the one-stop shop for healthcare innovation in Rhône-Alpes, France. It aims to support the emergence and development of innovative technologies, products and services in 4 main strategic areas: human medicine, veterinary medicine, in vitro diagnostics, medical devices and medical technologies. Focused on infectious diseases since its creation in 2005, Lyonbiopole is now supporting ambitious projects and companies in other fields like cancer, nutrition, metabolic diseases and neurosciences. In 2014, Lyonbiopole represented a community of 176 members: 4 world-class leaders as Lyonbiopole's founders (Sanofi Pasteur, bioMérieux, Merial, BD) -- 18 Research Centers including 3 Hospital University Centers and almost 154 SMEs. Lyonbiopole received in November 2014, the Gold label awarded by the "European Cluster Excellence Initiative".
More information: www.lyonbiopole.com
About Lyon and ONLYLYON
ONLYLYON is both the brand and the territorial marketing program carried by 13 local institutional partners whose goal is to boost Lyon's international reach and attractiveness.
Lyon Métropole is the second largest metropolitan area in France and one of Europe's 10 principal urban regions. It has 1.6 million inhabitants and is structured around sectors of excellence including health, cleantech and digital.
Contact Information:
Contact:
Dalyce Semko Suanez
Open2America
Phone: (403) 869-3259
E-Mail: d.suanez@open2america.com